Solving major substance use disorder treatment gaps during COVID-19

COVID-19 didn’t just disrupt vacations and office small talk. It also stress-tested a U.S. substance use disorder (SUD)
treatment system that already had cracksthen asked it to do cartwheels in a mask while the floor was on fire.
The result: more missed appointments, longer waitlists, new barriers (hello, childcare and quarantines), and a surge
in overdose risk that hit some communities especially hard.

But the pandemic also forced a rare, useful thing in American health care: rapid policy change. Telehealth expanded.
Methadone rules loosened. Buprenorphine access improved. Outreach got creative. Many of those “emergency”
workarounds proved to be… actually better. The big question now is how to turn the best pandemic-era lessons into
a long-term blueprint that closes treatment gaps instead of just moving them around.

Why treatment gaps widened during COVID-19

1) Demand went up while capacity went down

The pandemic amplified the exact conditions that can worsen SUD: isolation, stress, unemployment, housing instability,
and disrupted routines. At the same time, many clinics reduced in-person visits, paused groups, or struggled with staffing.
“More need” plus “less capacity” equals predictable chaos.

2) The system leaned too hard on in-person logistics

Before COVID-19, many services were built around physical presencedaily or frequent clinic visits, paper forms,
in-person counseling requirements, and limited cross-state practice. When travel, exposure risk, and lockdown rules arrived,
those assumptions collapsed.

3) Inequities weren’t newCOVID-19 just put them in bold font

Communities facing racism, poverty, unstable housing, rural distance, and limited broadband often had the hardest time
accessing care. The digital divide turned “telehealth expansion” into “telehealth expansion… for people with a decent signal.”
And overdose risk has not been evenly distributed across groups, underscoring why “one-size-fits-all” solutions fail.

The pandemic “experiment” that changed treatment access

Telehealth: from “nice-to-have” to “how we kept the lights on”

During COVID-19, federal flexibilities allowed more SUD care to happen remotely, including parts of medication treatment
for opioid use disorder (MOUD). Telehealth reduced travel time, time off work, childcare hurdles, and the “waiting room
of awkward eye contact.” It also helped reach rural patients and people who’d avoided care due to stigma.

Importantly, research during the pandemic found telehealth buprenorphine initiation and ongoing care could support
retention and quality outcomes comparable to, and sometimes better than, in-person approachesespecially when programs
were intentional about follow-up and support.

Methadone take-home doses: fewer lines, more stability

Opioid treatment programs (OTPs) historically required many patients to show up frequentlysometimes dailyfor supervised
methadone dosing. COVID-era flexibilities allowed larger numbers of take-home doses for eligible patients, reducing crowding
and exposure risk. Over time, evidence and policy momentum supported making some of these flexibilities more durable,
shifting the focus toward clinical judgment and patient stability rather than rigid schedules.

Buprenorphine access: fewer bureaucratic hoops

Another barrier that predated COVID-19 was provider friction: special training and waiver requirements, confusing rules,
and fear of scrutiny. Federal changes removed the “X-waiver” requirement for prescribing buprenorphine, aiming to mainstream
this evidence-based treatment in routine medical practice. That doesn’t automatically create more providers overnight, but it
removes a major “paper wall” that kept care out of reach.

What the data says: access improved, but gaps remain

Medication treatment is still underused

Even with policy progress, a striking treatment gap persists: only a fraction of people with opioid use disorder receive
medications like buprenorphine or methadone. That gap matters because MOUD reduces overdose risk and supports recovery.
If your system’s best tools sit on the shelf, it’s not a tool problemit’s an access problem.

Overdose trends: progress after a brutal peak

The U.S. experienced extremely high overdose mortality during and after the pandemic years. More recent national reporting
has shown meaningful declines compared with prior peaksencouraging, but still far above pre-pandemic levels in many places.
This matters for treatment planning: falling numbers are not permission to take the foot off the gas; they’re proof that
access strategies can work.

Six strategies to close SUD treatment gaps (the stuff worth keeping)

1) Make “low-barrier” the default, not a special program

Low-barrier care means fewer delays and fewer hoops: same-day or next-day appointments, walk-in options, minimal
preconditions, and rapid starts for medications when appropriate. In a pandemic, it prevented drop-offs. In normal times,
it prevents people from losing the brief moment when they’re ready for help.

• Offer rapid access pathways for MOUD initiation.
• Reduce unnecessary paperwork and repeated assessments.
• Use “warm handoffs” from emergency departments, hospitals, and outreach teams.

2) Keep telehealthbut fix the digital divide

Telehealth works best when it’s a choice, not a mandate. The goal should be hybrid care: video when helpful, phone when
video isn’t possible, and in-person when clinically needed or preferred. To avoid leaving patients behind, programs can:

• Support phone-based care when video isn’t available.
• Provide private telehealth spaces through community partners (libraries, shelters, community clinics) when appropriate.
• Use simple tech workflows (text reminders, one-click links) and patient coaching.

Policy matters here. Continued federal action on telemedicine prescribing flexibilities has been crucial to preventing
disruption in care while longer-term rules are finalized.

3) Expand methadone access while protecting safety and dignity

The pandemic showed that expanded take-home methadone can be safe and can support retentionwhen programs use good
clinical judgment and patient-centered safeguards. That doesn’t mean “anything goes.” It means designing rules around
real life: work schedules, transportation limits, caregiving, and health risks.

• Use individualized take-home plans based on stability and support needs.
• Improve coordination with pharmacies and medical providers for side-effect monitoring and interactions.
• Reduce punitive responses to relapse; focus on engagement and safety.

4) Build a workforce that can actually meet demand

Removing a waiver is helpful, but workforce shortages are still real. Closing gaps requires clinicians, counselors, peers,
case managers, and community health workersplus the administrative support that keeps them from drowning in forms.

• Train primary care, ED, and hospital teams to start and maintain MOUD.
• Integrate addiction medicine consults into general medical settings.
• Fund peer recovery specialists and community health worker roles as core staff, not “nice extras.”

5) Treat SUD like health care, not a scavenger hunt

Fragmented systems force patients to “prove deservingness” at every step: separate intake sites, separate counseling sites,
separate insurance authorizations, separate everything. Integration reduces drop-off:

• Co-locate services (primary care + MOUD + mental health + social services).
• Use a single care plan that follows the patient across settings.
• Coordinate transitions from hospital, jail/prison, and detox to ongoing outpatient care.

6) Pair treatment with harm reduction and recovery supports

Treatment is the foundation, but people also need practical supports: housing help, food access, transportation vouchers,
legal aid, and employment services. Meanwhile, harm reduction toolslike widespread naloxone accessreduce death risk and
keep the door open for treatment.

The “either/or” debate (treatment versus harm reduction) is a time-waster. The “both/and” approach is what saves lives.

Specific examples of solutions that scaled during COVID-19

Emergency departments that started buprenorphine immediately

Some hospitals expanded “ED-initiated buprenorphine” workflows during the pandemic: start medication promptly, then connect
patients to follow-up via telehealth or rapid-access clinics. This can turn a crisis visit into a care entry point rather than
a revolving door.

Mobile outreach and “treatment where people are”

Mobile units, street medicine teams, and community partnerships helped reach people who couldn’t or wouldn’t come to a clinic
especially those experiencing homelessness. During COVID-19, meeting people outdoors or in community settings often became the
most realistic way to stay connected.

OTPs that redesigned care around patients’ lives

When take-home doses expanded, some programs used the freed-up time to provide more targeted support: check-ins for those who
wanted them, proactive outreach, and better coordination for mental health and chronic conditions. Fewer daily lines didn’t have
to mean “less care.” It could mean “more meaningful care.”

What still blocks progress (and how to fix it)

Stigma and fear-based policy

Stigma doesn’t just hurt feelingsit shapes regulations, funding, and clinic culture. Policies built on mistrust can push
people out of care. Fix: adopt person-first language, prioritize engagement over punishment, and align regulations with
evidence rather than stereotypes.

Payment and incentives that reward volume over outcomes

Some payment structures still incentivize frequent in-person visits even when they’re unnecessary. Fix: reimburse telehealth
appropriately, fund care coordination, and pay for outcomes that matter (retention, reduced overdose risk, improved function).

Uneven state implementation

Federal policy changes often require state alignment, licensing adjustments, and local operational buy-in. Fix: provide technical
assistance, track adoption, and use funding levers to encourage evidence-based implementation.

What “good” looks like after COVID-19

Closing SUD treatment gaps isn’t about returning to 2019. It’s about keeping the best pandemic-era changes and upgrading the rest.
A stronger system would:

• Offer fast, low-barrier entry to care, including MOUD.
• Use hybrid care models (telehealth + in-person) without leaving low-connectivity communities behind.
• Allow clinically appropriate methadone take-homes and reduce unnecessary daily attendance.
• Mainstream buprenorphine prescribing across health care settings.
• Integrate treatment with mental health care and social supports.
• Invest in harm reduction and overdose prevention alongside treatment.

Experiences from the field : what treatment gaps felt like during COVID-19

If you want to understand treatment gaps, don’t start with a policy memo. Start with the morning alarm.

In early COVID-19, plenty of people trying to stay in recovery woke up to a new daily math problem: “How do I get help without
getting sick, losing my job, or breaking quarantine?” For someone used to a routinebus ride, clinic line, quick hello from the
nursesuddenly the routine was gone. One day the group therapy room existed; the next day it was a closed door and a phone number.
For people who rely on structure, that shift landed like someone quietly removing the handrails from a staircase.

Patients described the emotional whiplash of being told, “Your care is essential,” while also hearing, “We can’t see you in person,”
“We’re short-staffed,” or “Call back next week.” Some had phones with unreliable service or limited data. Others shared crowded living
spaces where privacy was basically a myth. Telehealth helped a lot of peoplebut for some, it also meant taking a sensitive medical
call in a parked car, outside a workplace, or in the only quiet corner they could find.

Meanwhile, many clinicians were improvising in real time. A counselor who used to rely on facial expressions in a group session had to
learn how to read a long pause on speakerphone. Nurses who knew patients by nameand by the subtle cues of “doing okay” versus “barely
hanging on”had to turn that intuition into structured check-ins. It wasn’t that staff stopped caring. It’s that the system asked them
to provide high-touch care through low-touch channels, while also worrying about their own health and their own families.

The methadone changes were a big moment. For some patients, take-home doses felt like someone finally believed them. People talked about
getting back hours of their liveshours they could spend working, parenting, or sleeping like a functional human being. For others, the
shift came with anxiety: “What if I mess this up?” or “What if my housing situation makes it hard to store medication safely?” The key
lesson wasn’t that take-homes are automatically perfect. The lesson was that when clinics partnered with patientsclear expectations,
supportive follow-up, and individualized plansflexibility could strengthen recovery rather than threaten it.

Another recurring story was how SUD treatment collided with basic needs. If you’re choosing between paying for transportation to a clinic
or paying for groceries, the system is asking you to make an impossible choice and then judging you for it. Programs that provided
practical supportsbus passes, flexible scheduling, proactive outreach, help navigating Medicaidoften saw better engagement. Not because
they had a magical secret, but because they reduced the everyday friction that makes treatment harder than it needs to be.

Finally, there was the exhaustion of uncertainty. Rules changed. Clinic hours changed. Telehealth rules were extended, then debated, then
extended again. Patients and providers both worried about sudden policy cliffswhat happens if a regulation changes and someone loses a
treatment pathway that finally worked for them? That’s why the post-COVID goal can’t be “temporary exceptions.” The goal has to be stable,
understandable access: a system where people don’t have to re-learn the rules of getting help every few months.

The pandemic was brutalbut it revealed something hopeful: when barriers drop, people show up. When care is reachable, recovery is more
reachable. The job now is to keep what worked, fix what didn’t, and stop acting surprised that health care works better when it’s designed
for humans with actual lives.

Conclusion

COVID-19 exposed major substance use disorder treatment gapsthen unintentionally helped prove how to close them. Telehealth expansion,
smarter methadone policies, easier buprenorphine prescribing, and low-barrier care models didn’t just “cope with the crisis.” They
demonstrated a more patient-centered baseline for the future. The next step is making these improvements reliable, equitable, and
scalableso access to treatment isn’t something you luck into, but something you can count on.